1.82

0.00% 0.01

Cabaletta Bio Inc (CABA)

Overview News Price History Option Chain Financials Why CABA Down? Discussions Forecast

Cabaletta Bio Inc stock is traded at $1.82, with a volume of 676.09K. It is up +0.00% in the last 24 hours and down -24.58% over the past month. Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Previous Close:

$1.81

Open:

$1.82

24h Volume:

676.09K

Relative Volume:

0.28

Market Cap:

$88.47M

Revenue:

Net Income/Loss:

$-67.68M

P/E Ratio:

-1.0964

EPS:

-1.66

Net Cash Flow:

$-54.24M

1W Performance:

-12.14%

1M Performance:

-24.58%

6M Performance:

-68.47%

1Y Performance:

-92.15%

1-Day Range:

$1.71

$1.92

1-Week Range:

$1.71

$2.0599

52-Week Range:

$1.71

$24.67

Cabaletta Bio Inc Stock (CABA) Company Profile

Name

Cabaletta Bio Inc

Sector

Healthcare (1189)

Industry

Biotechnology (675)

Phone

(267) 759-3100

Address

2929 ARCH STREET, PHILADELPHIA, PA

Employee

154

Twitter

@CabalettaBio

Next Earnings Date

2024-11-07

Latest SEC Filings

CABA's Discussions on Twitter

Compare CABA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CABA Cabaletta Bio Inc	1.83	88.47M	0	-67.68M	-54.24M	-1.66
VRTX Vertex Pharmaceuticals Inc	476.99	121.85B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	697.93	76.83B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	618.18	37.96B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	241.99	30.69B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	269.08	29.71B	3.32B	-860.46M	-1.04B	-8.32

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-10-24	Initiated	UBS	Buy
Feb-05-24	Initiated	Jefferies	Buy
Nov-29-23	Initiated	William Blair	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-19-23	Initiated	Stifel	Buy
Sep-05-23	Initiated	Citigroup	Buy
Jul-18-23	Initiated	Guggenheim	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-08-21	Initiated	Wells Fargo	Overweight
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jun-30-21	Initiated	Mizuho	Buy
Jan-08-21	Initiated	Chardan Capital Markets	Buy
Oct-13-20	Initiated	H.C. Wainwright	Buy
Nov-19-19	Initiated	Cowen	Outperform
Nov-19-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Morgan Stanley	Overweight

View All

Cabaletta Bio Inc Stock (CABA) Latest News

09:55 AM

Cabaletta Bio stock hits 52-week low at $1.75 amid sharp decline - Investing.com India

09:55 AM

09:47 AM

Cabaletta Bio to Present at TD Cowen 45th Annual Health Care Conference - MSN

09:47 AM

Feb 26, 2025

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference - TradingView

Feb 26, 2025

Can Cabaletta Bio's Conference Appearance Signal New Autoimmune Treatment Progress? - StockTitan

Feb 26, 2025

Feb 25, 2025

Is Now The Time To Buy Cabaletta Bio Inc (NASDAQ: CABA) Stock? - Stocks Register

Feb 25, 2025

Cabaletta Bio Reveals Promising Clinical Data for Autoimmune Therapy - MSN

Feb 25, 2025

Feb 23, 2025

HC Wainwright Reiterates Buy Rating for Cabaletta Bio (NASDAQ:CABA) - MarketBeat

Feb 23, 2025

Feb 19, 2025